Given the debilitating impact of COVID-19 (Coronavirus) on the Cardiac Surgery Devices market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Cardiac Surgery Devices market and understand how market players are adopting new strategies to mitigate the impact of the pandemic. The report provides both quantitative and qualitative information of global Cardiac Surgery Devices market for period of 2018 to 2025. Continue reading →

May 15, 2020 13:30 ET | Source: Medtronic plc Milestone Results Presented as Late-Breaking Clinical Science at SCAI 2020 DUBLIN, May 15, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced results from two late-breaking clinical trials presented virtually at the 2020 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. Continue reading →

May 14, 2020 14:50 ET | Source: Amarin Corporation plc First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA in prespecified tertiary endpoint analyses Results of prespecified tertiary endpoint analyses consistent across different types of coronary revascularization procedures, including urgent, emergent, and elective interventions Percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) reduced by 32% and 39%, respectively, in post hoc exploratory analyses DUBLIN, Ireland and BRIDGEWATER, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data from the REDUCE-IT study presented by Benjamin E. Peterson, M.D., Brigham and Womens Hospital Heart & Vascular Center and Harvard Medical School, at the Society for Cardiovascular Angiography & Interventions 2020 Scientific Sessions, showed that administration of 4 g/day of VASCEPA (icosapent ethyl) resulted in a significant 34% reduction in first coronary revascularizations versus placebo (p Continue reading →

Expands CytoSorb E.U. label that now includes the reduction of two major blood thinners, rivaroxaban (Xarelto) and ticagrelor (Brilinta), during on-pump cardiothoracic surgery with the goal of reducing serious perioperative bleeding complications MONMOUTH JUNCTION, New Jersey, May 12, 2020 /PRNewswire/ --CytoSorbents Corporation(NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announces that CytoSorb is now approved and immediately available in the European Union for the removal of rivaroxaban (Xarelto- Bayer, Jansenn/Johnson & Johnson), a widely-used Factor Xa inhibitor and novel oral anticoagulant (NOAC), during cardiothoracic surgery requiring cardiopulmonary bypass (CPB) Continue reading →

Doctors call for overhaul to elective surgery model to help with COVID-related backlog Karen Murias waited 18 months for surgery and finally got a date for a procedure she hoped would bring relief of excruciating pain in her shoulder and abdomen. But half an hour after getting a call on a Sunday in mid-March that a liver cyst would be removed the next day, her surgeon phoned to say the operation had been postponed because beds were being saved for a possible influx of COVID-19 patients Continue reading →

A London doctor has treated a surgeon who saved his life 20 years ago after the man was admitted to hospital with coronavirus. Dr Shakil Rahman, a respiratory consultant, cared for Venkatachalam Chandrasekaran, known as Mr Chandra, when he was admitted to Epsom General hospital with COVID-19. Twenty years ago Mr Chandra, a cardiothoracic surgeon at St George's Hospital in Tooting, performed a cardiac bypass on Dr Rahman when he had a heart attack in his late 30s. Continue reading →